Safety of early nadroparin for prevention deep vein thrombosis in patients with intracerebral hemorrhage
10.3760/cma.j.issn.1673-4165.2014.12.002
- VernacularTitle:早期那屈肝素预防脑出血患者深静脉血栓形成的安全性
- Author:
Shuangshuang GU
;
Jun ZHANG
;
Ling HAN
;
Jin LI
;
Qiming LI
;
Jian QIAN
;
Dujuan SHA
- Publication Type:Journal Article
- Keywords:
Cerebral Hemorrhage;
Venous Thromboembolism;
Heparin,Low-Molecular-Weight;
Risk Assessment;
Nadroparin
- From:
International Journal of Cerebrovascular Diseases
2014;22(12):902-906
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the safety of early subcutaneous injection of a low-dose low molecular weight heparin (LMWH) nadroparin for prevention of deep vein thrombosis (DVT) in patients with spontaneous intracerebral hemorrhage (sICH).Methods The patients with sICH who early using nadroparin or lower limb intermittent pneumatic compression (IPC) for prevention of DVT were enrolled.A nadroparin group continuously injected nadroparin 0.4 ml/d subcutaneously for 10 days at day 4 after admission and an IPC group used lower limb IPC.Head CT was reexamined and hematoma volume changes were evaluated at day 3,5,and 14 after admission.The hemorrhagic events during the course of treatment were documented,and the lower limb DVT was examined by color Doppler sonography.Results A total of 94 patients with acute sICH (n =41 in the nadroparin group,n =53 in the IPC group) who early use of nadroparin or IPC for prevention of DVT were enrolled.Fourteen patients had lower limb DVT,5 (12.2％) of them were in the nadroparin group and 9 (17.0％) of them were in the IPC group.However,there was no significant difference in the incidence of DVT between the two groups (x2 =0.418; P =0.518).During the treatment,no patient experienced increased intracranial hematoma and rebleeding.Conclusion Early subcutaneous injection of low-dose nadroparin for the prevention of DVT in patients with sICH is safe.
